栖霞建设（600533）公告，预计2025年半年度实现归属于上市公司股东的净利润约为5500万元至8000万 元，预计2025年半年度实现归属于上市公司股东的扣除非经常性损益的净利润约为5100万元至7600万 元。2025年6月，南京星叶云汇府、南京星叶翰锦院、南京星叶栖悦湾项目竣工交付，导致公司结转的 销售收入较上年同期大幅增加，本报告期归属于上市公司股东的净利润扭亏为盈。 ...

江苏世纪同仁律师事务所 关于南京栖霞建设股份有限公司 2024 年年度股东大会的 法 律 意 见 书 致：南京栖霞建设股份有限公司： 本所及本所律师根据贵公司的委托，就贵公司 2024 年年度股东大会（下称 "本次股东大会"）的有关事宜，根据《中华人民共和国证券法》、《中华人民共 和国公司法》和《上市公司股东大会规则》等法律、法规(下统称"相关法律法 规")以及《南京栖霞建设股份有限公司章程》（下称"《公司章程》"）的有关规 定，出具本法律意见。 为出具本法律意见之目的，本所律师出席了贵公司本次股东大会，并根据现 行法律、法规的有关规定及要求，按照律师行业公认的业务标准、道德规范和勤 勉尽职精神，对贵公司提供的与本次股东大会召开有关的文件和事实进行了核查 和验证，在此基础上，本所律师对法律意见出具之日及以前所发生的事实发表法 律意见如下： 一、关于本次股东大会的召集 1、本次股东大会由贵公司董事会召集。 贵公司董事会于 2025 年 4 月 30 日在《中国证券报》、《上海证券报》、《证券 时报》和上海证券交易所网站 www.sse.com.cn，发布"关于召开 2024 年年度股 东大会的通知"，定于 20 ...

证券代码：600533 证券简称：栖霞建设 公告编号：2025-019 南京栖霞建设股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 29 日 | 1、出席会议的股东和代理人人数 | 299 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 463,838,250 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.1750 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会采取现场投票与网络投票相结合的方式召开，召集人为公司董 事会，由董事长江劲松先生主持。本次会议的召集、召开和表决方式均符合《公 司法》及《公司章程》的规定。 1 (五)公司董事、监事和董事会秘书的出席情况 公司副总裁兼董事会秘书王海刚先生出席本次会议；公司副总裁朱金宁先生 ...

Group 1 - The company will hold the "2024 Annual and 2025 Q1 Performance Briefing" on May 29, 2025, from 15:30 to 16:30 [2][3] - The meeting will be conducted via a WeChat mini-program for interactive online communication [2][3] - Key personnel attending the meeting include Chairman and President Jiang Jinsong, Independent Director Zhang Xiulian, Vice President and Board Secretary Wang Haigang, and Chief Accountant He Zhengwu [3] Group 2 - Investors can submit questions via email to the company before the meeting on May 29, 2025 [4] - Investors can participate in the meeting by searching for "Yao Diao Yan" mini-program on WeChat and selecting "Online Briefing" [4][5] - Contact information for inquiries includes phone number 025-85600533 and email invest@chixia.com [7]

| 证券代码：600533 | | | 证券简称：栖霞建设 | 编号：临 2025-018 | | --- | --- | --- | --- | --- | | 债券简称：22 | 栖建 | 01 | 债券代码：185951 | | | 债券简称：23 | 栖建 | 01 | 债券代码：240284 | | | 债券简称：24 | 栖建 | 02 | 债券代码：240546 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、说明会类型 公司已于 2025 年 4 月 30 日在《中国证券报》、《上海证券报》、《证券 时报》 及上海证券交易所网站（www.sse.com.cn）上披露了 2024 年年度报告及 摘要、2025 年第一季度报告。为让广大投资者更全面深入的了解公司经营成果 和财务状况，公司决定采用网络远程的方式举行"2024 年度暨 2025 年第一季度 业绩说明会"。 二、说明会召开的时间和方式 召开时间：2025 年 5 月 29 日（星期四）15:30-16:30 南京栖霞建设 ...

Group 1 - The core point of the announcement is that Nanjing Gaoke Co., Ltd. plans to reduce its shareholding in the company by up to 31.5 million shares, which is 3% of the total share capital [2] - As of the announcement date, Nanjing Gaoke holds 92.59308 million shares, accounting for 8.818% of the company's total share capital [2] - The reduction plan includes selling up to 10.5 million shares through centralized bidding and up to 21 million shares through block trading [2] Group 2 - There are no concerted actions among the shareholders involved in the reduction [3] - The actual start of the reduction may be postponed if the company's stock is suspended [4] - Nanjing Gaoke has not made any prior commitments regarding shareholding ratios, quantities, or reduction methods [5] Group 3 - The implementation of the reduction plan is subject to uncertainties due to stock price fluctuations and regulatory changes [6] - The reduction plan is not expected to lead to a change in the company's control [7] - The plan complies with relevant regulations and guidelines regarding shareholder reductions [7]

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 一、减持主体的基本情况 | | --- | | 股东名称 | 南京高科股份有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | □否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | □否 | | | 其他： | | | | 持股数量 | 92,593,080股 | | | | 持股比例 | 8.818% | | | 1 | 证券代码：600533 | | | 证券简称：栖霞建设 | 公告编号：2025-017 | | --- | --- | --- | --- | --- | | 债券简称：22 | 栖建 | 01 | 债券代码：185951 | | | 债券简称：23 | 栖建 | 01 | 债券代码：240284 | | | 债券简称：24 | 栖建 | 02 | 债券代 ...